Page 1 of 2

Form PTO-1449 (Rev. 2-97 by App.)

U.S. Department of Commerce Patent and Trademark Office

Att'y Docket No. Serial No. Applicant:

09/\_ Arrigo DeBenedetti et al. July 26, 2001

00S08 DeBenedetti

## INFORMATION DISCLOSURE CITATION

(use Several Sheets if Necessary)

Filing Date Group Art Unit:

(use Several Sheets in Nocosan y	130
U.S. PATENT E	OCUMENTS Class Subcl. File Date
Date Date	Name Class
Exam. Initial DOCUMENT VO.	
	Partinent Pages, etc.)

				1		
			hor, Title, Date, Pertine	ent Pages,	etc.)	
	PROCLIMEN	ITS (Including Aut	hor, Title, Date, Ferting	n of the HS	SVtk gene	for the
	OTHER DOCOME	virus-mediated tis	sue-targeted expression	99)		
-	OTHER DOCUMEN  Inderson, L.M. et al., "Adeno  treatment of breast cancel  Inthony, B. et al., "Overexpre	Ctho proto	oncodene-translation :			
	Anthony, B. et al., "Overexpro cell lines," Int.J.Cancer, vo Binley, K. et al., "An adenovi	ol. 65, pp. 858-863	(1995)	atment of	ischaemic	disease and
$\checkmark$	cancer, Gene The	·ithe	cancer connection, "	•••		
9°	Clemens, M.J. <i>et al.</i> , Transi pp. 1-23 (1999)	initiation factor-4E	in superficial and mus	and tumou	r progress	ion, Di. J.
9	Cancer, vol. 82, pp. 161	-166 (2000)	umors: its possible role	in progres	ssion of m	alignancies,
ges	Int. J. of blochonius	- Thoran	Annroach Intough in	and.		
82/	DeFatta, R.J. et al., "A Car Gene," submitted to Na DeFatta, Robert J., "The E	ture Medicine, July Lukaryotic Translat Incer Gene Therap	/ 9, 2001 ion Initiation Factor (ell y," a Dissertation, subn sity and Agricultural ar	F) 4E Durin nitted to the nd Mechan	e Graduat ical Colleg	e Faculty of le, catalogued
X/	and placed on the she	If on March 20, 200	cer Cells Based on Tra	anslational	Control of	a Suicide
Se (	Gene," submitted to	erapeutic agents fo	or treatment of establish al progress," Current O	pinion in O	ncology, v	ol. 4, pp. 1130
W.	metastatic sproduct		cancer " European J	ournal of C	ancer, vol	. 35(6), pp.
of	Gomez-Navarro, J. et al. 2039-2057 (1999) Hall, S.J. et al., "Cooper	ative therapeutic e	ffects of androgen abla nd ganciclovir therapy in 3 (1999).	ation and a	denovirus ental prost	-mediated herp ate cancer, "
The same of the sa	Cancer Gene Therap	py, vol. 6, pp. 54-6	or adenocarcinoma of t	he prostate	e: A phase	l clinical trial,"
90	Herman, J.R. et al.,"In s Human Gene Thera	ov vol. 10, pp. 12	39-1249 (1999)			
170	Human Gene Thera	ру, чол.		ONCIDE		<del></del> ·

EXAMINER		٨
	-	A

DATE CONSIDERED

\* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Page 2 of 2

Form PTO-1449 (Rev. 2-97 by App.)

U.S. Department of Commerce Patent and Trademark Office

Att'y Docket No. Serial No. Applicant: Filing Date

Group Art Unit:

00S08 DeBenedetti 09/ Arrigo DeBenedetti et al. July 26, 2001

## INFORMATION DISCLOSURE CITATION

(use Several Sheets if Necessary)

(use octors: 511	1			_	
		COUMENTS			
		OCUMENTS Name	Class	Subcl.	File Date
Exam. Initial Document No.	Date				

7 K	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)  aloss, M. et al., "Distribution of retroviral vectors and vector producer cells using two routes of
1	administration in rats, Construction administration factor elF4E: a survey of its
$\psi$	expression in bleast caronic many
WK	and AUG COUGHS for transfer an
	4E: Implications for tulifor an argued the secondarion study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 triyinding (latzmann, D Phase I/II dose-escalation stu
	pp. 2585-2894 (1996)  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5" non-coding region  Koromilas, A.E. et al., "mRNAs containing extensive secondary
1/	4153-4158 (1992)  7 -4-24 "Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo
P	retroviral gene trierapy, riamento de la carte initiation factor elF-4E mRNA in a broad spectrum of
	transformed cell lines, Carros and office in surgical margins may predict
W	Nathan, C.O. et al., "Detection of the proto-oncogene et 42 in odiginal in odi
gr/	Hematology, vol. 24, pp. 525 55 The Hematology ranslation factors en 42
gr/	and elf-Zaipha in transfermed and early event daring synthesis initiation factor elf4E is an early event daring
90/	colon carcinogenesis, one of cancer; what have we done and where are we going?
	Roth, J.A. et al., "Gene therapy for carried the carried to the National Cancer Institute, vol. 89(1), p. 21-39 (1997) the National Cancer Institute, vol. 89(1), p. 21-39 (1997) Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein scott

**EXAMINER** 

DATE CONSIDERED

4-16-02

\* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.